Alzheimer's Disease International

What Alzheimer's Disease International does

Alzheimer's Disease International (ADI) is the international federation of Alzheimer and dementia associations, founded in 1984 and headquartered in London with legal incorporation as a 501(c)(3) in Illinois, USA. It operates as a non-profit membership organization with 105 national member associations across more than 100 countries, supported by a lean central team of 1-10 staff, a Chair of the Board, an Acting CEO, and regional offices in Jakarta (Asia Pacific, est. 2013) and Buenos Aires (Americas). ADI's mission is to improve the quality of life for people living with dementia and their families worldwide through advocacy, awareness, research dissemination, and capacity building; it has held official relations with the World Health Organization since 1996 and in 2025 secured dementia's formal recognition as a leading noncommunicable disease in the UN Political Declaration.

ADI's core offerings are knowledge, convening, and capacity-building products rather than technology. Flagship outputs include the annual World Alzheimer Report series, the biennial Global Conference (1,500+ delegates from 90+ countries), the From Plan to Impact policy-progress series, the newly launched Alzheimer's Disease Atlas (2025, supported by Eli Lilly), World Alzheimer's Month (September) campaign, Alzheimer University and Twinning capacity-building programmes, ADI Accreditation, and advocacy toolkits such as the 2026 Dementia as a Non-Communicable Disease Advocacy Toolkit. Distribution is federated: ADI designs global resources that its 105 national associations localize and deliver to people living with dementia, carers, clinicians, and policymakers, supplemented by direct digital distribution through alzint.org and social channels.

ADI's revenue model combines donations (individuals, foundations such as Mary Oakley Foundation, and corporate partners), membership contributions from the 105 national associations, and biennial conference fees. Corporate sponsorship is a material revenue line, with Gold sponsors including Eli Lilly and Bristol Myers Squibb, and a broader Bronze/sponsor tier spanning Roche, Biogen, Eisai, Johnson & Johnson, AbbVie, GE Healthcare, Lantheus, MSD, Nutricia, Lundbeck, Otsuka, Parexel, and Acadia. The organization is governed by a volunteer Elected Board from member associations and reports operating surpluses are reinvested in advocacy, publications, and capacity building. ADI discloses no revenue figures and does not develop proprietary technology, AI, or software products.

Name

Alzheimer's Disease International

Legal name

Alzheimer's Disease International

Website

https://alzint.org

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

1–10 employees

Short description

Alzheimer's Disease International is a non-profit federation of 105 national Alzheimer and dementia associations across 100+ countries, delivering advocacy, research reports, training, and awareness campaigns to improve life for people with dementia, with WHO official relations since 1996.

Ownership category

akta.pro rank

Product category

Non-profit Health Advocacy and Dementia Care Services

NAICS

Services for the Elderly and Persons with Disabilities (62412), Social Advocacy Organizations (8133)

SIC

Services-Membership Organizations (8600), Services-Social Services (8300)

akta.pro primary industry

Elder Services & Aging Support (BPAGAEAF)

akta.pro secondary industries

Dementia Care Coordination & Care Planning (HSABAEAJ), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Dementia advocacy services
• Global health awareness campaigns
• Non-profit federation services
• Dementia care training programmes
• Dementia policy research

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others, Technology or R&D

Revenue model

1. Donations: ADI accepts donations from individuals, corporations, and foundations. The organization is a 501(c)(3) non-profit registered in the USA with tax ID 36-3366783. Donations are tax-deductible for US taxpayers. Friends of ADI is a UK-registered charity enabling tax-effective giving for UK donors.
2. Conference fees: ADI holds international conferences every two years with delegates from over 100 countries. Revenue is generated through conference registrations.
3. Membership contributions: ADI has 105 member associations worldwide. Member associations access benefits including one-to-one support, training programs like Alzheimer University, and participation in global network activities.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Core offering

Alzheimer's Disease International (ADI) is a not-for-profit international federation that supports 105 national Alzheimer and dementia associations across more than 100 countries. Its core offerings are advocacy, research publications, awareness campaigns, training programmes (Alzheimer University, Twinning Programme), accreditation for dementia care education, biennial international conferences, and policy coordination with the WHO and UN to position dementia as a global health priority.

Product overview

Alzheimer's Disease International (ADI) is a not-for-profit international federation of Alzheimer and dementia associations operating as an advocacy and awareness organization, not a technology product company. ADI's offerings consist of research publications (World Alzheimer Reports, From Plan to Impact series), knowledge platforms (Alzheimer's Disease Atlas), training programmes (Alzheimer University, Twinning Programme), certification services (ADI Accreditation), advocacy toolkits, and awareness campaigns/events (World Alzheimer's Month, ADI Conference, End of Year Forecast). These services work together to support ADI's mission of raising awareness, reducing stigma, and advocating for dementia to be a global health priority across 105 member associations in over 100 countries.

Differentiator

Problem solved

Functional benefit

Products and services

• World Alzheimer Reports Comprehensive series of annual reports providing global socioeconomic information on dementia, each covering a different thematic topic with expert essays, case studies, and recommendations for policy and practice.
• Alzheimer's Disease Atlas First-of-its-kind platform mapping the global landscape of Alzheimer's disease, providing country-by-country insight into dementia policies, diagnosis timelines, research activity, support services, and relevant charities to assess preparedness for Alzheimer's and related dementias.
• ADI Accreditation Accreditation programme for carers, trainers, and providers of dementia care training programmes through successful completion of evaluation against ADI standards for quality dementia care education.
• Alzheimer University Comprehensive educational programme providing practical workshops aimed at building and strengthening capacity in advocacy and policy, alongside care and support for people living with dementia, their carers and families.
• Twinning Programme Development programme connecting ADI member associations globally to enable effective sharing of good practice and knowledge exchange between Alzheimer and dementia associations worldwide.
• ADI International Conference International conference held every two years, the longest-running global conference on dementia, uniting researchers, scientists, clinicians, allied healthcare professionals, people living with dementia, family members, care professionals, and association staff from around the world.
• World Alzheimer's Month Annual international awareness campaign taking place every September, coordinated by ADI with focus on World Alzheimer's Day on September 21, to raise awareness and challenge stigma around dementia globally.
• Dementia as a Non-Communicable Disease: Advocacy Toolkit Resource toolkit for advocates, policymakers, NGOs, caregivers, and health professionals providing materials to campaign for recognition of dementia as an NCD in national and local policy.
• From Plan to Impact Annual report series tracking WHO Member States' progress towards implementing the targets of the Global Action Plan on the Public Health Response to dementia.
• End of Year Forecast Annual event featuring globally renowned experts discussing the latest scientific perspectives on dementia innovation, treatments, and diagnostics, hosted in collaboration with Edelman.

Quantifiable outcome

• 75% of people with dementia are estimated to be living without a diagnosis globally
• +2 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

19 partnerships are on record, tiered core, major and minor.

• World Health Organization (WHO)coreStrategic or Co-development Partner · 1 January 1996ADI has been in official relations with WHO since 1996. The organization regularly delivers statements at WHO meetings and works closely on the Global Action Plan on the Public Health Response to Dementia 2017-2025. ADI produces 'From Plan to Impact' reports monitoring progress towards WHO plan targets.
• Alzheimer EuropecoreStrategic or Co-development PartnerNon-profit NGO made up of 39 member associations from 35 countries, aiming to provide voice to people with dementia and their carers, make dementia a European priority, promote rights-based approach, support research, and strengthen the European dementia movement.
• Alzheimer Ibero América (AIB)coreStrategic or Co-development PartnerInternational federation of Alzheimer's associations and foundations, made up of full members in 21 Ibero-American countries.
• Dementia Alliance InternationalcoreStrategic or Co-development PartnerNon-profit exclusively of people living with dementia, seeking to represent, support, and educate others living with the disease, and the wider dementia community. Individuals with diagnosis can join this partner organization.
• World-Wide FINGERS (WW-FINGERS)coreStrategic or Co-development PartnerADI is a partner in this project which builds on the FINGER model - the first randomized controlled trial demonstrating cognitive benefits using multi-domain lifestyle intervention. WW-FINGERS tests, adapts, and optimizes the FINGER model across different populations and cultural settings.
• Global Brain Health InstitutemajorStrategic or Co-development PartnerPartnership focused on brain health training and education programs.
• Global Observatory for Ageing and Dementia Care at King's College LondonmajorStrategic or Co-development PartnerAcademic partnership for research collaboration on ageing and dementia care.
• HelpAge InternationalmajorStrategic or Co-development PartnerGlobal network promoting the rights of older people, collaboration on dementia in ageing contexts.
• International Alliance of Patients' Organizations (IAPO)majorStrategic or Co-development PartnerAlliance focused on patient advocacy and healthcare policy.
• NCD AlliancecoreStrategic or Co-development PartnerFollowing ADI's successful advocacy, dementia was recognized as a leading NCD in the 2025 UN Political Declaration. ADI collaborates with NCD Alliance on integrated health messaging and advocacy.
• Pan American Health Organization (PAHO)majorStrategic or Co-development PartnerRegional office of WHO for the Americas, collaboration on dementia policy in the Americas region.
• World Dementia CouncilmajorStrategic or Co-development PartnerInternational body working on dementia research and care priorities.
• World Young Leaders in Dementia (WYLD)minorStrategic or Co-development PartnerNetwork of young professionals working in dementia.
• Swedish Care InternationalminorStrategic or Co-development PartnerPartnership on care approaches and dementia care practices.
• Global Alliance For the Rights of Older People (GAIRO)minorStrategic or Co-development PartnerAlliance focused on rights of older people including those with dementia.
• London School of Economics and Political Science (LSE)coreStrategic or Co-development PartnerADI partnered with LSE on the STRiDE project (Strengthening responses to dementia in developing countries). The four-year project works across seven countries (Brazil, India, Indonesia, Jamaica, Kenya, Mexico, South Africa) across 12 work packages to build research capacity and develop evidence for national dementia plans.
• University College London (UCL)majorStrategic or Co-development PartnerADI sits on advisory boards for UCL projects including CST International (focusing on Brazil, India, and Tanzania) and INDUCT project (Interdisciplinary network for dementia using current technology). ADI provides training through a yearly summer school.
• EdelmanmajorStrategic or Co-development PartnerPublic relations firm collaborating with ADI on End of Year Forecast events. Hosted 2025 Diagnostics Revolution event with 1,400 virtual participants and full in-person attendance in London.
• EU Joint Programme for Neurodegenerative Disease Research (JPND)majorStrategic or Co-development PartnerADI is external collaborator on COGNISANCE Project, a 3-year initiative working in 5 countries to co-design dementia diagnosis and post diagnostic care tools.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Alzheimer Europe: European federation of 39 Alzheimer associations across 35 countries. Directly comparable to ADI as a regional dementia federation with advocacy, member services, and policy work targeting EU institutions and WHO Europe.
• Alzheimer's Association (US): US national Alzheimer association and one of ADI's founding members (1984). Comparable as a national federation member providing research funding, care services, advocacy, and awareness campaigns — ADI operates as the global umbrella for such national bodies.
• Alzheimer Ibero América (AIB): Ibero-American federation of Alzheimer associations in 21 countries. Direct peer to ADI as a regional federation, complementing ADI's Americas regional office in Buenos Aires and operating in the same advocacy and capacity-building verticals.
• Alzheimer's Society (UK): UK national Alzheimer charity and one of ADI's founding members. Comparable as a major national member association delivering research, helplines, advocacy, and care services — a key in-country partner for ADI's awareness campaigns.
• Dementia Alliance International: Non-profit organization led by people living with dementia. Direct peer and named ADI partner, focused on advocacy, education, and representation of diagnosed individuals — overlaps significantly with ADI's mission and target audiences.

Regional players

• Alzheimer's Research UK: UK-based charity funding dementia research and awareness. Comparable as a national/regional dementia organization with research funding and public campaigns, operating in one of ADI's largest member countries.

Emerging players

• NCD Alliance: Global alliance advocating for noncommunicable diseases. ADI collaborates with NCD Alliance following dementia's inclusion in the 2025 UN Political Declaration on NCDs — comparable as a fellow advocacy coalition in the same policy ecosystem.
• HelpAge International: Global network promoting rights of older people, including people with dementia. Named ADI partner; comparable as a global aging-focused NGO with UN advocacy, but broader in mandate than ADI.
• World Dementia Council: International body driving global action on dementia research and care. Overlaps with ADI on policy advocacy and research prioritization, though narrower in scope (research-focused rather than full federation).
• Global Brain Health Institute: Equity-based institute focused on brain health training and dementia prevention. Named ADI partner; comparable in brain health and dementia education focus, but more academic/research-oriented than ADI.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/alzdisint
• YouTubeyoutube.com/@AlzDisInt
• Facebookfacebook.com/alzdisint
• LinkedInlinkedin.com/company/alzdisint
• Instagraminstagram.com/alzdisint

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alzheimer's Disease International